Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Bone Fracture Clinical Trial

Official title:

A Multicenter Study to Evaluate the Enhancement of Bone Regeneration and Healing in the Extremities by the Use of Autologous BonoFill-II

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03024008
• Other study ID #: CP-BNS05
• Status: Recruiting
• Phase: Phase 1/Phase 2
• Start date: July 27, 2017
• Est. completion date: September 2022

Study information

• Verified date: June 2021
• Source: BonusBio Group Ltd
• Contact: Nimrod Rozen, MD, PhD
• Phone: +972-4-649-4201
• Email: nimrod_rozen[@]hotmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this clinical study is to evaluate the safety and the efficacy of BonoFill-II as an autologous bone-regenerating graft in the reconstruction of deficient bone in two clinical indications:

1. Long and short bone extra-articular comminuted fracture

2. Long and short bones extra and intra articular defect /Gap or non-union, incapable of self-regeneration

Description:

Primary Endpoint:

Safety: to establish that the transplantation of BonoFill-II into bone defect/gap is safe under the following conditions:

• No treatment-related appearance of heterotrophic bone ossification

• No excessive bone formation at the transplantation sites

• No abnormalities in the treated sites

Efficacy: to establish that the transplantation of BonoFill-II into bone defect/gap is effective under the following conditions:

Bone continuity rate, measured radiographically by CT at 6 and 12 months.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 20
• Est. completion date: September 2022
• Est. primary completion date: June 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 80 Years

Eligibility

Inclusion Criteria:

• Long and short bones extra articular comminuted fracture or

• Long and short bones extra and intra articular defect/gap or non union, incapable of self-regeneration

Exclusion Criteria:

• Age is under 18 or above 80

• A simple fracture manageable by one definitive treatment

• Pregnant or lactating women

• Patients with active infection anywhere in the body except in the injured bone site that is in question and needs osteogenic treatment.

• Subjects with recorded medical history diseases such as heart diseases, renal failure.

• Subject treated currently with systemic steroids.

• Subjects with known autoimmune diseases, such as Addison's disease, Celiac disease - sprue (gluten-sensitive enteropathy), Dermatomyositis, Graves disease, Hashimoto's thyroiditis, Multiple sclerosis, Myasthenia gravis, Pernicious anemia, Reactive arthritis, Rheumatoid arthritis, Sjogren syndrome, Systemic lupus erythematosus.

• Subjects diagnosed with osteoporosis

• Subjects that have a known scar healing problem (keloid formation).

• Subjects treated with Bisphosphonate drugs

• Oncology patients in treatment

• Subjects who received chemotherapy or radiotherapy treatment in the past

• Subjects participating in another clinical trial 30 days prior to and during the study period.

• Drug addicts and psychiatric patients patients incapable of giving consent.

• Subjects with a known history of any significant medical disorder, which in the investigator's judgment contraindicates the subject's participation.

• Subjects with any known allergy for local/general anesthesia.

• Positive serology for either HIV, hepatitis B or hepatitis C.

• Abnormal clinically significant laboratory test and findings, as per the investigator's judgment.

Related Conditions & MeSH terms

• Bone Fracture
• Fractures, Bone

Intervention

Biological:
• BonoFill-II
Surgery will be performed under local or general anesthetics according to the Investigator's and anesthesiologist discretion. A standard orthopedic approach will be made according to the fracture site.Then the transplantation of BonoFill-II into the fracture site and the fixation of the fracture by intramedullary nail or plate and screws or external fixator as required will be performed. internal fixation (plate and screws and intramedullary nails) will not be routinely removed. External fixators will be removed upon achievement of satisfactory bone union.

Locations

Country	Name	City	State
Israel	Emek Medical Center	'Afula
Israel	Hillel Yafe	Hadera
Israel	Carmel Medical Center	Haifa
Israel	Rambam Health Campus	Haifa
Israel	Meir Medical Center	Kfar Saba

Sponsors (1)

Lead Sponsor	Collaborator
BonusBio Group Ltd

Country where clinical trial is conducted

Israel, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects with treatment-emergent appearance of safety issues	Subjects will be followed-up for appearance of heterotrophic bone ossification, excessive bone formation and/or any abnormalities in the treated site, in the proximal or distal joint by visual examination of the transplantation site and by Xray. Outcome measure will be reported in number of incidences. Results will be aggregated into one single value of each one of the safety issues, indicating the number of subjects displaying these treatment-related safety issues.	Throughout the post-intervention 12-month follow-up
Secondary	Bone continuity	Bone union will be assessed by Xray and confirmed by CT. Outcome measure will be reported by Results will be aggregated into one single value indicating the number of subjects displaying bone union/continuity.	Starting 4-week follow-up and through to the end of the 12-month follow-up
Secondary	Time to union	Time to bone union will be recorded. Outcome measure will be reported in months and weeks.	Starting 4-week follow-up and through to the end of the 12-month follow-up
Secondary	Weight bearing ability	clinical examination of weight bearing ability for lower extremities or coffee-cup weight bearing ability for upper extremities	3, 6 and 12 months
Secondary	Lack of pain at the surgical site	Clinical evaluated by movements of the joints above and below the surgical site area	3, 6 and 12 months